James Dentzer, Curis CEO

Pa­tient death trig­gers a sec­ond clin­i­cal hold for Curis as FDA seeks more da­ta

Af­ter a pa­tient died in a Phase I/IIa clin­i­cal tri­al for leukemia, the FDA has im­posed an ad­di­tion­al par­tial hold on Curis’ on­go­ing Phase I/II lym­phoma study with the same drug.

Last week, Curis al­ready paused en­roll­ment for this tri­al af­ter the FDA put its leukemia tri­al on par­tial hold. The holds for these two tri­als may thwart Curis’ rapid reg­is­tra­tion goals for the ther­a­py in ques­tion, emavusert­ib, or CA-4948.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.